Grünenthal Invests US$88 million (€80 million) to Open Production Site in Latin America
Introduction:
Grünenthal invests US$88 million (€80 million) in its Latin American production facilities to enhance the reliability of medicine supply for patients.
Features:
The 50,000-square-meter campus is Ecuador's largest and most advanced pharmaceutical manufacturing plant, specialising in solid, semi-solid, and liquid medications.
This new facility will have the capacity to produce up to 300 million high-quality tablets annually for pain patients across 17 European countries.
In Chile, a 3,500-square-meter solid dosage plant has undergone a complete refurbishment, transforming it into a world-class manufacturing site with a production capacity of 1.8 billion tablets per year.
In Quito, Ecuador, a new 1,800-square-meter plant has been established to produce 300 million high-quality tablets annually, catering to pain patients in 17 European countries.
This state-of-the-art facility further solidifies its position as a leading pharmaceutical manufacturer. The advanced technology implemented not only enhances production but also benefits employees by providing specialised training.
The goal is to achieve certification from the European Medicines Agency (EMA) by November 2025, allowing the supply of medicines from Chile to Europe.
Specifications:
| Name | Grünenthal |
| Type | New Construction |
| Budget | US$88 million (€80 million) |
| Year | 2025 |
